Peptides›Metabolic›5-Amino-1MQ + NADH (Blend)

5-Amino-1MQ + NADH (Blend)

/ Two-component blend - 5-Amino-1-methylquinolinium (5-A1MQ; selective NNMT inhibitor small molecule) + NADH (reduced nicotinamide adenine dinucleotide)

TIER 3 · PreclinicalN = 0 · TESTING PENDING

ALIAS · 5-A1MQ + NADH · 5A1MQ/NADH stack · NNMT inhibitor + NADH

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequence— sequence not captured —

MW · —CLASS · Two-component blend - 5-Amino-1-methylquinolinium (5-A1MQ; selective NNMT inhibitor small molecule) + NADH (reduced nicotinamide adenine dinucleotide)CATEGORY · Metabolic

Tier 3 by component inheritance. The base 5-amino-1-methylquinolinium (5-A1MQ) is a small-molecule selective NNMT inhibitor with rodent metabolic data; the NADH co-component has separate redox-cofactor literature in unrelated indications. The vendor-marketed blend has no published combination pharmacology, no PK study, and no Phase 1 or later trial.

§ B · Mechanism of action

The 5-A1MQ component is a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that consumes nicotinamide and S-adenosylmethionine to form 1-methylnicotinamide. NNMT inhibition raises tissue NAD+ availability and methyl-donor pools and in adipocyte models reduces lipogenesis. The NADH co-component is the reduced form of nicotinamide adenine dinucleotide; vendor marketing positions it as direct redox-cofactor support to complement NNMT inhibition. No published mechanistic study of the specific 5-A1MQ + NADH combination exists; the rationale is inference from the two component literatures.

§ C · Human clinical evidence

No combination evidence. Component evidence: 5-A1MQ rodent metabolic data (Neelakantan 2018) reported reduced fat mass in diet-induced-obese mice; NNMT-knockout mouse phenotype (Kraus 2014) supports the broader NNMT axis as a metabolic target. NADH supplementation has separate small-trial literature in chronic fatigue syndrome and Parkinson disease that does not generalise to a metabolic small-molecule blend. No human study of either component for the specific indications associated with the blend.

§ D · Primary literature

PubMed29155147Neelakantan H et al. — Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice · Biochemical Pharmacology · rodentSelective small-molecule NNMT inhibitors including 5-amino-1-methylquinolinium reduced adiposity and improved metabolic parameters in diet-induced-obese mice; established proof-of-concept for NNMT inhibition as a metabolic target.Limitations: Rodent only; single-laboratory characterisation; no human PK or efficacy data.2018

PubMed24717514Kraus D et al. — Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity · Nature · rodentAntisense knockdown of NNMT in white adipose tissue protected mice from diet-induced obesity, increased energy expenditure, and reshaped polyamine and methyl-donor flux; foundational paper for NNMT as a metabolic target.Limitations: Knockdown rather than pharmacological inhibition; rodent only; tissue-specific effects vary by model.2014

§ F · Safety signal

No combined human safety database. 5-A1MQ has no published Phase 1 data of any kind. Oral NADH is generally regarded as well tolerated in supplement-trial settings at typical doses, but the safety of co-administration with an investigational NNMT inhibitor has not been characterised.

§ H · Regulatory status

Regulatory status

FDA status:: Not FDA-approved

§ I · Notable gaps and controversies

The blend is a vendor marketing construct, not a pharmacologically validated combination. Vendors sometimes present 5-A1MQ + NADH as a recognised stack with established evidence; the published record contains only the separate component literatures, neither of which has reached human trials. Buyers cannot verify the identity, purity, or stoichiometry of vendor-prepared blends without independent analytical testing.